AWSensors LiqBiopSens

Molecular diagnostics

The LiqBiopSens by AWSensors, is a liquid biopsy platform for early detection and monitoring of colorectal cancer.

After talking to Tecan, we chose the Omni Flex, as Cavro is a brand that offers good value and high quality. We also knew that, as a complete liquid handling system, the Cavro Omni Flex would significantly reduce the time taken to develop the liquid biopsy platform

Maribel Rocha, application scientist at AWSensors

Detection of genetic markers with a liquid biopsy platform

Advanced Wave Sensors (AWSensors) focus is on high frequency, quartz crystal microbalance with dissipation measurement (QCMD) sensors and sensor arrays – as well as control electronics and software – and microfluidics to allow miniaturization of the systems and sample volumes for specific analyte detection. AWSensors is working with its Horizon 2020 partners across Europe to develop a reliable, rapid, non-invasive liquid biopsy assay to detect colon and lung cancer.

 

AWSensors is creating an automated platform for the analysis of liquid biopsies for circulating tumor DNA by combining ultrasensitive acoustic wave sensors and microfluidic cartridge technology with novel chemical reagents. In order to accomplish this, AWSensors had to develop a liquid handling platform that could accommodate a microfluidic device and a 24-sensor array for simultaneous monitoring of multiple biomarkers. AWSensors is using the Cavro® Omni Flex robot, equipped with a Cavro XMP 6000 Pump and Cavro Air Displacement Pipettor (ADP) along with their sensor array technology on the Liqbiopsens platform.

 

AWSensors is laying a key role in the pan-European Horizon 2020 LiqBiopSens and Catch-U-DNA projects which are aimed at replacing the labor-intensive, costly, and occasionally biased PCR-based approach currently used for the detection of genetic markers.